Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia
Public ClinicalTrials.gov record NCT00590577. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of this study are to evaluate the efficacy and safety of 3 fixed doses of paliperidone palmitate administered i.m. after an initial loading dose of 150 mg eq. in the deltoid muscle followed by either deltoid or gluteal injections for a total of 13 weeks of treatment as compared with placebo in patients with schizophrenia.
Study identification
- NCT ID
- NCT00590577
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 652 participants
Conditions and interventions
Conditions
Interventions
- Paliperidone palmitate 25 mg eq. Drug
- Paliperidone palmitate 150 mg eq. Drug
- Placebo Drug
- Paliperidone palmitate 100 mg eq. Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2007
- Primary completion
- Feb 29, 2008
- Completion
- Feb 29, 2008
- Last update posted
- Jun 3, 2014
2007 – 2008
United States locations
- U.S. sites
- 32
- U.S. states
- 14
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Anaheim | California | — | — |
| Not listed | Cerritos | California | — | — |
| Not listed | Escondido | California | — | — |
| Not listed | Glendale | California | — | — |
| Not listed | La Palma | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | National City | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Santa Ana | California | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Kissimmee | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | North Miami | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Hoffman Estates | Illinois | — | — |
| Not listed | Kingsport | Indiana | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Lake Charles | Louisiana | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Rockville | Maryland | — | — |
| Not listed | Cedarhurst | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Olean | New York | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Moore | Oklahoma | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Arlington | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
Recently updated Schizophrenia trials
Other public records listing Schizophrenia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07615426: A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia Recruiting
- NCT07788755: NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia Not yet recruiting
- NCT07783373: Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia Active, not recruiting
- NCT07772349: Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 3) Not yet recruiting
- NCT07680114: Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls Recruiting
- NCT07734493: A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00590577, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2014 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00590577 live on ClinicalTrials.gov.